2-氟-1-苯乙胺 | 929971-85-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-氟-1-苯乙胺
• 中文别名: α-（氟甲基）苄胺
• 英文名称: 2-fluoro-1-phenylethan-1-amine
• 英文别名: (±)-2-fluoro-1-phenylethan-1-amine；2-fluoro-1-phenylethanamine
• CAS: 929971-85-7
• 化学式: C₈H₁₀FN
• mdl: MFCD09040683
• 分子量: 139.173
• InChiKey: KSWGCLOZHMSHGB-UHFFFAOYSA-N

物化性质

• 沸点：
  214.7±25.0 °C(Predicted)
• 密度：
  1.096 g/mL at 25 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• WGK Germany：
  3
• 海关编码：
  2921499090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
: α-(Fluoromethyl)benzylamine
Product name
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 929971-85-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin corrosion (Category 1B), H314
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
C Corrosive R34, R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H314 Causes severe skin burns and eye damage.
Precautionary statement(s)
P280 Wear protective gloves/ protective clothing/ eye protection/ face
protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P310 Immediately call a POISON CENTER or doctor/ physician.
Supplemental Hazard none
Statements
Other hazards
Possible sensitizer.

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 2-Fluoro-1-phenylethanamine
alpha-(Fluoromethyl)benzenemethanamine
Formula : C8H10FN
Molecular Weight : 139,17 g/mol
CAS-No. : 929971-85-7
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
alpha-(Fluoromethyl)benzylamine
CAS-No. 929971-85-7 Skin Corr. 1B; H314 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a
physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Air sensitive. Store under inert gas.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: -0,643
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
LD50 Oral - rat - 9.000 mg/kg
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: GU4800000
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2735 IMDG: 2735 IATA: 2735
UN proper shipping name
ADR/RID: AMINES, LIQUID, CORROSIVE, N.O.S. (alpha-(Fluoromethyl)benzylamine)
IMDG: AMINES, LIQUID, CORROSIVE, N.O.S. (alpha-(Fluoromethyl)benzylamine)
IATA: Amines, liquid, corrosive, n.o.s. (alpha-(Fluoromethyl)benzylamine)
Transport hazard class(es)
ADR/RID: 8 IMDG: 8 IATA: 8
Packaging group
ADR/RID: II IMDG: II IATA: II
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-1-苯乙胺 、 6-溴-4-氯噻吩[2,3-D]嘧啶 以 正丁醇 为溶剂， 反应 72.0h， 以80%的产率得到(rac)-6-bromo-N-(2-fluoro-1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  Structure–activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor

  摘要：

  Based on the thieno[2,3-d]pyrimidine scaffold, a series of new 4-amino-6-aryl thienopyrimidines have been prepared and evaluated as EGFR tyrosine kinase inhibitors. The in vitro activity was found to depend strongly on the substitution pattern in the 6-aryl ring, the stereochemistry, and the basicity at the secondary 4-amino group. A stepwise optimization by combination of active fragments led to the discovery of three structures with EGFR IC50 < 1 nM. The most potent drug candidate had an IC50 of 0.3 nM towards EGFR and its mutants L858R and L861Q. Studies using human cancer cell lines and an EGFR-L858R reporter cell system revealed good cellular potency, verifying the identified thienopyrimidines as promising lead structures. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.042
• 作为产物：
  描述：

  2-氟苯乙酮 在 ammonium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 2-氟-1-苯乙胺
  参考文献：
  名称：

  转氨酶的催化混杂：通过形式串联加氢脱氟/脱氨反应制备对映体富集的β-氟胺

  摘要：

  转氨酶是用于工业生物催化的有价值的酶，并且能够制备光学纯的胺。对于这些转化，它们需要胺供体（酮的胺化）或胺受体（外消旋胺的脱氨）。本文显示转氨酶与芳香族β-氟胺反应，因此导致在不存在胺受体的情况下同时对映选择性脱卤和脱氨反应形成相应的苯乙酮衍生物。一系列外消旋的β-氟胺通过串联加氢脱氟/脱氨反应以动力学方式拆分，从而得到相应的胺，其ee高达99％以上。该协议是利用转氨酶催化混杂作为新型转化工具的第一个例子。

  DOI：

  10.1002/anie.201510554

文献信息

• PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：US20200247815A1

  公开（公告）日：2020-08-06

  The present invention relates to pyrazolyl-containing tricyclic derivative, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protease such as ERK (MAPK) inhibitor in the treatment of cancers, bone diseases, inflammatory diseases, immunological diseases, nervous system diseases, metabolic diseases, respiratory diseases and heart diseases, wherein the definition of each substituent in the general formula (1) is the same as defined in the description.

  本发明涉及吡唑基含有的三环衍生物，其制备方法及其用途。具体而言，本发明涉及一种如通式(I)所示的化合物，其制备方法及含有该化合物的药物组合物，以及将其用作蛋白酶，如ERK（MAPK）抑制剂，用于治疗癌症、骨疾病、炎症性疾病、免疫疾病、神经系统疾病、代谢性疾病、呼吸系统疾病和心脏疾病，其中通式（1）中每个取代基的定义与描述中定义的相同。
• Enantioenriched 1-aryl-2-fluoroethylamines. Efficient lipase-catalysed resolution and limitations to the Mitsunobu inversion protocol
  作者：Thor Håkon Krane Thvedt、Erik Fuglseth、Eirik Sundby、Bård Helge Hoff

  DOI：10.1016/j.tet.2010.06.081

  日期：2010.8

  inversion protocol starting with enantioenriched 1-aryl-2-fluoroethanols using phthalimide as nucleophile was employed in the synthesis of the (S)-1-aryl-2-fluoroethylamines. Both the inversion efficiency and yield depended on the aromatic substituents. For six of the substrates, clean inversion of the stereochemistry was observed. However, racemisation and low yields were the result when electron-donating

  八个1-芳基-2-氟乙胺的两种对映体均以1-芳基-2-氟乙酮为原料合成。使用南极假丝酵母的脂肪酶B和甲氧基乙酸乙酯作为酰基供体对胺进行动力学拆分，得到96.99％ee的（R）-胺和> 99.5％ee的（S）-甲氧基乙酰胺。关于反应温度，酰基给体浓度，水活度和底物结构的变化，分离度很强。其他九种脂肪酶制剂未能催化该反应或对映选择性低。其次，在合成（（S）时，采用以苯二甲酰亚胺为亲核试剂的对映体富集的1-芳基-2-氟乙醇为原料的Mitsunobu转化方案。）-1-芳基-2-氟乙胺。转化效率和产率均取决于芳族取代基。对于六种底物，观察到立体化学的完全反转。但是，当芳族环上存在供电子性取代基时，外消旋化和低收率是结果。当用氰基或硝基取代时，会发生意想不到的氟消除，从而限制了这些转化的收率。使用圆二色性确定1-芳基-2-氟乙胺的绝对构型。
• Chemoenzymatic Dynamic Kinetic Resolution of Amines in Fully Continuous-Flow Mode
  作者：Emese Farkas、Márk Oláh、Attila Földi、János Kóti、János Éles、József Nagy、Cristian Andrei Gal、Csaba Paizs、Gábor Hornyánszky、László Poppe

  DOI：10.1021/acs.orglett.8b03676

  日期：2018.12.21

  In this study, lipase-mediated dynamic kinetic resolution (DKR) of various benzylic amines (1a–g) is presented which is realized in a so far unprecedented fully continuous-flow system. The DKR process applying sol–gel immobilized lipase B from Candida antarctica as biocatalyst, palladium on 3-aminopropyl-functionalized silica as racemization catalyst, isopropyl 2-ethoxyacetate as acylating agent, ammonium

  在这项研究中，提出了脂肪酶介导的各种苄基胺（1a – g）的动态动力学拆分（DKR），这是迄今为止前所未有的完全连续流动的系统所实现的。DKR工艺采用南极假丝酵母的溶胶-凝胶固定化脂肪酶B作为生物催化剂，3-氨基丙基官能化二氧化硅上的钯作为外消旋催化剂，2-乙氧基乙酸异丙酯作为酰化剂，甲酸铵作为氢和氮源，以及2-甲基-2在调节的压力下，以-丁醇为溶剂，以中等至良好的收率提供了所需的产物，并具有优异的对映体过量。
• Diastereoselective Alkylation of Glycinates by Assistance of Intramolecular Potassium⋅⋅⋅Fluorine Interactions
  作者：Takashi Yamazaki、Seiji Kawashita、Tomoya Kitazume、Toshio Kubota

  DOI：10.1002/chem.200901984

  日期：2009.11.2

  K⋅⋅⋅F intramolecular chelation: Glycinates with fluorine‐containing substituents on the nitrogen atom were found to be potent substrates for the present diastereoselective alkylation. Alkylation occurred by way of the corresponding enolate, which possessed a rigid bicyclo [3.3.0] structure. A fluorine atom on the enolate played a pivotal role by constructing an intramolecular interaction with a potassium

  K⋅⋅⋅F分子内螯合：发现氮原子上带有含氟取代基的甘氨酸盐是当前非对映选择性烷基化的有效底物。烷基化反应是通过相应的烯醇化物进行的，该烯醇化物具有刚性的双环[3.3.0]结构。烯醇盐上的氟原子通过与钾原子建立分子内相互作用而起关键作用。
• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Charrier Jean-Damien

  公开号：US20130095193A1

  公开（公告）日：2013-04-18

  The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

  本发明涉及一种有用的ATR蛋白激酶抑制剂化合物。本发明还涉及包含该发明化合物的药学上可接受的组合物；使用该发明化合物治疗各种疾病、疾患和病况的方法；制备该发明化合物的过程；用于制备该发明化合物的中间体；以及在体外应用中使用化合物的方法，例如研究生物和病理现象中的激酶、介导这些激酶的细胞内信号转导途径的研究，以及新的激酶抑制剂的比较评估。该发明化合物的化学式为I，其中变量如本文所定义。